Pleuropulmonary blastoma (PPB) is a rare and aggressive pediatric lung cancer originating in the tissues of the lungs and pleura. Cancer research has significantly advanced our understanding of PPB, particularly its genetic underpinnings. Mutations in the DICER1 gene are strongly associated with PPB, providing a genetic marker for early diagnosis and familial screening. Current research is focused on understanding the molecular pathways influenced by DICER1 to develop targeted therapies. Innovative treatment strategies, including personalized medicine and immunotherapy, are being explored to improve outcomes. Despite its rarity, PPB research is pivotal in enhancing survival rates and quality of life for affected children, underscoring the importance of ongoing genetic and therapeutic studies.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China